Company news
Exicure, Inc. (NASDAQ:XCUR) news
Exicure, Inc. news releases on 6ix. Latest, Aug 25, 2020: Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod
Press releases — page 3
Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod
August 24, 2020
Exicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress
August 11, 2020
Exicure, Inc. Added to Russell 2000® Index
June 28, 2020
Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)
June 15, 2020
Exicure Announces Appointment of Dr. Douglas E. Feltner as Chief Medical Officer
May 18, 2020
Exicure, Inc. Reports First Quarter 2020 Financial Results and Corporate Progress
May 13, 2020
Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board
April 6, 2020
Exicure Provides Business Update Amid COVID-19 Pandemic
March 29, 2020
Exicure, Inc. Reports Full Year 2019 Financial Results and Corporate Progress
March 2, 2020
Exicure Announces the Closing of its Offering of Common Stock
December 22, 2019
Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock
December 18, 2019
Exicure Announces Proposed Public Offering of Common Stock
December 17, 2019
Exicure Announces First Neurological Development Program in Friedreich’s Ataxia and Expands Scientific Advisory Board
December 15, 2019
Exicure Reports Activity of AST-008 in Patients with Merkel Cell Carcinoma and Will Enroll Patients in Phase 2 Study
December 10, 2019
Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders
November 13, 2019
Exicure Reports Third Quarter 2019 Financial Results and Recent Developments
November 6, 2019
Exicure Presents Positive Biomarker Results from Clinical Trial of XCUR17
October 15, 2019